• Altimmune appointed Peter Greenleaf and Alex Howarth to its board, effective Nov. 2, 2026.
• Greenleaf most recently served as CEO of Aurinia Pharmaceuticals, overseeing its transition from development-stage company to commercial enterprise.
• Howarth most recently served as CFO of Madrigal Pharmaceuticals, leading strategic planning for its transition to a commercial organization.
• John M. Gill, Mitchel Sayare and Klaus O. Schafer will retire from the board at the 2027 annual meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270800PRIMZONEFULLFEED9853651) on October 27, 2026, and is solely responsible for the information contained therein.